Table 3.

Primary and Key Secondary Endpoints, by Treatment Group

Endpoint	Placebo (n = 21)	Dupilumab (n = 19)	OR or HR (95% CI)	P Value
Proportion of patients alive and free of mechanical ventilation by day 28	18 (85.7)	15 (78.9)	Unadjusted OR: 1.60 (.31–8.30)	.57
			Adjusted OR: 2.45 (.40–15.10)	.34
Proportion of patients alive and free of mechanical ventilation by day 60	16 (76.2)	17 (89.5)	Unadjusted OR: 0.38 (.06–2.22)	.28
			Adjusted OR: 0.44 (.07–2.96)	.40
Mortality by day 28	3 (14.3)	1 (5.3)	Unadjusted HR: 0.35 (.04–3.32)	.36
			Adjusted HR: 0.06 (.003–1.59)	.09
Mortality by day 60	5 (23.8)	2 (10.5)	Unadjusted HR: 0.40 (.08–2.05)	.27
			Adjusted HR: 0.05 (.004–.72)	.03

Primary endpoint was ventilator-free survival by day 28. Secondary endpoints were ventilator-free survival by day 60, mortality by day 60, and mortality by day 28. Proportions are listed as No. (%). The differences in the ventilator-free survival proportions were evaluated using logistic regression, adjusted for sex. Differences in mortality risk were evaluated in the Cox regression, adjusted for sex and time-varying mechanical ventilation.

Abbreviations: CI, confidence interval; HR, hazard ratio; OR, odds ratio.